Grant ID | RP180810 |
Awarded On | August 24, 2018 |
Title | Controlling the Activity of Anticancer T Cells by Inducing Replicative Senescence |
Program | Academic Research |
Award Mechanism | High Impact/High Risk |
Institution/Organization | Baylor College of Medicine |
Principal Investigator/Program Director | Maksim Mamonkin |
Cancer Sites | Leukemia, Lymphoma |
Contracted Amount | $200,000 |
Lay Summary |
Certain cancers can be effectively treated — and even cured — by enhancing cells from a patient’s own body. Changing these specialized immune cells, called “T cells,” to enable them recognize and kill tumor cells has a number of advantages over conventional cancer drugs. For instance, T cells can easily find tumors, multiply and remain in the body until the tumor is cleared. One downside to these powerful “living drugs” is that their long-term activity in patients hard to control or even predict, which sometimes results in unwanted toxicities. For example, T cells trained to recognize leukemia cells also attack normal blood cells responsible for preventing infections, among other functions. ... |